Oxford BioDynamics PLC (AIM:OBD, OTC:OXBOF) executive chairman Iain Ross talked with Proactive's Stephen Gunnion about the company’s new partnership with Google Cloud, a move he described as a major growth catalyst for both Oxford BioDynamics and the field of 3D genomics.
Ross outlined how the deal will support the global scaling of the company’s EpiSwitch platform by making it cloud native, allowing faster deployment, greater accessibility, and continuous updates. “This deal will accelerate the adoption of our 3D genomics platform. It’ll expand into different markets and it will build recurring revenues,” he said.
By leveraging Google’s cloud, AI, and machine learning infrastructure, Oxford BioDynamics aims to streamline data processing and reach new partners in the pharmaceutical and biotech industries. Ross highlighted that the partnership boosts credibility by aligning OBD with Google and its other life sciences initiatives like DeepMind and AlphaFold.
The company expects in due course to benefit from new revenue streams through licensing, access fees, and one-off purchases. Ross said the cloud transition enables wider use of the platform and access to broader diagnostics and clinical markets. He noted that the addressable market for genomics could reach $175 billion within the next decade.
Visit Proactive's YouTube channel for more interviews and updates. Don’t forget to like this video, subscribe, and turn on notifications for future content.
#OxfordBioDynamics #GoogleCloud #3DGenomics #EpiSwitch #PrecisionMedicine #BiotechNews #GenomicsInnovation #CloudComputing #HealthcareAI #PharmaTech #LifeSciences #MolecularDiagnostics
